2026-01-24 - Analysis Report
**Abbott Laboratories (ABT) Financial Analysis Report**

### 1. Comparison with S&P 500 (VOO)

* Ticker: ABT
* Company Name: Abbott Laboratories
* Cumulative Return (last day): **53.94%**
* Cumulative Return (S&P 500, VOO): **126.41%**
* Divergence (max: 70.30, min: -72.50, current: -72.50, relative divergence: 0.00%): **-72.50**

### 2. Recent Stock Price Fluctuations

* Close: **$107.42**
* Last-Market: {'price': 107.42, 'previousClose': 108.61, 'change': -1.1}
* 5-Day SMA: **$115.93**
* 20-Day SMA: **$123.00**
* 60-Day SMA: **$125.07**

### 3. RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence

* Market Risk Indicator (MRI): **0.70** (High Investment Recommended: 0.9~1.0, Medium Investment: 0.7~0.9, Low Investment: 0.4~0.7, Very Risky: <0.4)
* RSI: **16.92**
* PPO: **-1.48**
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: **0.00** (flat)
* 7-Day Rank change: **164 (+)** (rank up)
* 7-Day Dynamic Expected Return change: **853.30 (+)** (improving)
* Expected Return (%): **-759.00%** (Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point)

### 4. Recent News & Significant Events

* ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth - TipRanks (news.google.com)
* Why Abbott Laboratories (ABT) Shares Are Sliding Today - Yahoo Finance (news.google.com)
* Abbott Laboratories: Buy This Dividend King On Sale Now (NYSE:ABT) - Seeking Alpha (news.google.com)
* Abbott Dives 7% On Quarterly Upset As Exact Close Looms - Investor's Business Daily (news.google.com)
* 2 Healthcare Names That Could Get a Big Boost From Earnings - MarketBeat (news.google.com)
* Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2 - Benzinga (news.google.com)

### 4-2. Analyst Opinions

* Analyst Consensus:
 + Key: Buy
 + Mean (1=StrongBuy~5=Sell): **1.76** (~Buy)
 + Opinions: **25**
 + Target Price (avg/high/low): **$137.07** / **$169.00** / **$122.00**

### 5. Recent Earnings Analysis

* | Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | **$11.37B** |
| 2025-07-30 | 1.02 | **$11.14B** |
| 2025-04-30 | 0.76 | **$10.36B** |
| 2024-10-31 | 0.94 | **$10.63B** |

The quarterly earnings show a decline in revenue and EPS in Q4 2025, which may have contributed to the recent stock price fluctuations. However, the Company has a history of recovering from such setbacks.

### 6. Financial Information

#### Revenue and Profitability

* | Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | **$11.37B** | **55.36%** |
| 2025-06-30 | **$11.14B** | **56.44%** |
| 2025-03-31 | **$10.36B** | **56.86%** |
| 2024-12-31 | **$10.97B** | **54.97%** |

The revenue has been steadily increasing over the years, with a slight decline in Q4 2025. The profit margin has also been volatile, ranging from 54.97% to 56.86%.

#### Capital and Profitability

* | Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | **$50.95B** | **3.23%** |
| 2025-06-30 | **$50.56B** | **3.52%** |
| 2025-03-31 | **$48.81B** | **2.71%** |
| 2024-12-31 | **$47.66B** | **19.36%** |

The equity has been steadily increasing over the years, with a slight decline in Q4 2025. The ROE has been volatile, ranging from 2.71% to 19.36%.

### 7. Comprehensive Analysis (Summary of previous items)

Based on the analysis, the stock price of Abbott Laboratories (ABT) has been volatile in recent times, with a cumulative return of 53.94% compared to 126.41% for the S&P 500 (VOO). The Market Risk Indicator (MRI) is at a medium risk level, indicating a moderate level of investment risk. The RSI and PPO indicators are bearish, suggesting that the stock may continue to decline in the short term. However, the analyst consensus is positive, with a mean rating of 1.76 (~Buy) and a target price of $137.07. The quarterly earnings analysis shows a decline in revenue and EPS in Q4 2025, but the Company has a history of recovering from such setbacks. The financial information shows a steady increase in revenue and equity over the years, with a volatile profit margin and ROE. Overall, the analysis suggests that the stock may be undervalued and presents a buying opportunity for long-term investors.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.